Characteristics of thawed autologous umbilical cord blood

  1. Emma H. Rosenau,
  2. Michele W. Sugrue,
  3. Michael Haller,
  4. Diann Fisk,
  5. Susan S. Kelly,
  6. Myron Chang,
  7. Wei Hou,
  8. Lamis Eldjerou,
  9. William Slayton,
  10. Christopher R. Cogle,
  11. John R. Wingard*

Article first published online: 10 FEB 2012

DOI: 10.1111/j.1537-2995.2011.03556.x

Issue

Transfusion

Transfusion

Volume 52, Issue 10, pages 2234–2242, October 2012

Additional Information

How to Cite

Rosenau, E. H., Sugrue, M. W., Haller, M., Fisk, D., Kelly, S. S., Chang, M., Hou, W., Eldjerou, L., Slayton, W., Cogle, C. R. and Wingard, J. R. (2012), Characteristics of thawed autologous umbilical cord blood. Transfusion, 52: 2234–2242. doi: 10.1111/j.1537-2995.2011.03556.x

Author Information

  1. From the Department of Medicine, the Department of Pediatrics, and the Department of Epidemiology and Health Policy Research, University of Florida, and Shands Hospital at the University of Florida, Gainesville, Florida; and the Department of Pediatrics Patient Care, University of Texas MD Anderson Cancer Center, Houston, Texas.

*John R. Wingard, MD, Price Eminent Scholar and Professor of Medicine, Director, Bone Marrow Transplant Program, Division of Hematology/Oncology, University of Florida College of Medicine, PO Box 100278, 1600 SW Archer Road, Gainesville, FL 32610-0278; e-mail: wingajr@ufl.edu.

Publication History

  1. Issue published online: 30 OCT 2012
  2. Article first published online: 10 FEB 2012
  3. Received for publication August 24, 2011; revision received December 13, 2011, and accepted December 19, 2011.

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (593K)

BACKGROUND: Autologous umbilical cord blood (AutoUCB) has historically been cryopreserved for potential use in hematopoietic transplantation. Increasingly, private AutoUCB banking is performed for therapies unavailable today. A Phase I trial using AutoUCB treatment for early pediatric Type 1 diabetes afforded us an opportunity to analyze characteristics of AutoUCBs.

STUDY DESIGN AND METHODS: Twenty AutoUCBs from AABB-accredited private cord blood banks (CBBs) were evaluated for collection, processing, cryopreservation, and thaw characteristics. Using a standardized thaw-wash method, AutoUCBs were assessed for viable total nucleated cells (vTNCs), viable CD34+ (vCD34+), and colony-forming unit–granulocyte-macrophage counts. Postthaw %vTNC recoveries were compared against processing characteristics and analyzed according to processing method, cryopreservation volume, concentration, container, and length of storage.

RESULTS: AutoUCB collection volumes (19.9-170 mL), cryopreserved TNC counts (7.6 × 107-3.34 × 109), %TNC processing recoveries (39%-100%), postthaw %vTNC recoveries (58%-100%), and %vCD34+ recoveries (26%-96%) varied widely. Regarding cell dose requirements, only 11% of evaluable AutoUCBs achieved the minimum TNC count of at least 9.0 × 108 to meet the National Cord Blood Inventory banking threshold, and only 50% met the minimum of 5.0 × 108 TNC count for Food and Drug Administration cord blood licensure eligibility. %vTNC recoveries correlated with %vCD34+ recoveries (R = 0.7; p = 0.03). Length of storage, cryopreservation volume, concentration, and container type did not affect postthaw %vTNC recoveries. CBB processing method, however, was associated with %vTNC postprocessing recoveries, with unmanipulated and plasma-depleted AutoUCBs having the highest postthaw %vTNC recovery, followed by RBC-depleted and density gradient–separated AutoUCBs.

CONCLUSION: The high variability and low counts found in AutoUCB banking suggest that further standardization of characterization, collection, and processing procedures is needed.

View Full Article (HTML) Get PDF (593K)